CHO Pharma, Inc. (TPEX:6586)

Taiwan · Delayed Price · Currency is TWD

94.00

+10.70 (12.85%)

Jun 18, 2026, 2:59 PM CST

135.00% (1Y)

Market Cap	20.12B +132.1%
Revenue (ttm)	1.43M -60.0%
Net Income	-290.01M
EPS	-1.36
Shares Out	214.01M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,501,957
Open	84.00
Previous Close	83.30
Day's Range	82.50 - 95.30
52-Week Range	22.75 - 95.30
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About CHO Pharma

CHO Pharma, Inc., engages in research and development of biotechnology in Taiwan. It develops glycoengineering platform technologies, including SAR-based glycoengineered biobetters; glycosite-specific antibody-drug conjugates (ADCs); novel antibodies and vaccines targeting novel carbohydrate antigens; and programs using its glycoengineering technologies. The company also provides CHOptimax, an in vitro enzymatic one-pot process that converts naked antibodies into glycoengineered biobetter or ADC. In addition, the company develops CHO-H01, which... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2012

Employees 47

Stock Exchange Taipei Exchange

Ticker Symbol 6586

Full Company Profile

Financial Performance

In 2025, CHO Pharma's revenue was 1.43 million, a decrease of -60.03% compared to the previous year's 3.58 million. Losses were -290.01 million, 36.6% more than in 2024.

Financial Statements